Tracers / [177Lu]Lu-eFAP-6
[177Lu]Lu-eFAP-6
Also written as [Lu-177]Lu-eFAP-6
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeting DOTA-conjugated small molecule (quinolinoyl-glycyl-2-cyanopyrrolidine derivative)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 39073475
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/in111-efap6/">in111-efap6</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | >95% | >95% | eFAP-6 | 39073475 2024 EJNMMI Radiopharm Chem Labeling reactions were performed in a solution containing sodium acetate (1 µL, 2.5 M), ascorbic and gentisic acids (10 µL, 50 mM), ethanol (10 µL), and complemented with Milli-Q water. — Radiolabeling of eFAP-6 with 111-indium and 177-lutetium was performed successfully with high radiochemical yield and purity (> 95%). |
Need this precursor?We can point you to suppliers for [177Lu]Lu-eFAP-6, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39073475. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39073475: 'eFAP-6 (1 nmol), 50 MBq [111In]InCl3 (Curium Pharma, Petten, The Netherlands) or 13–20 MBq [177Lu]LuCl3'. Stage set/updated at stage 23 from PMID 39073475: 'In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions.'.